ESGCT Congress 2024

Take a look at our posters

Poster presenters:

• Luka Bevc, Scientist, Sartorius BIA Separations
• Ivana Petrovič Koshmak, Head of Upstream Process Development, Sartorius BIA Separations

Date and time: 22 – 25 October, 2024

Posters:

Lentiviral Downstream Process Optimisation and Design of Experiments on CIM QA 0.05 mL Monolithic 96-Well Plates

Lentiviral vectors are being increasingly used as tools for stable integration of large gene inserts into the genomes of both dividing and non-dividing cells. With 3rd and 4th generation of lentiviral vectors being incompetent of replication, they also offer a relatively safe tool for more widespread use. Currently, lentiviral based therapies are primarily ex-vivo, such as CAR-T, however recent animal studies have successfully demonstrated their use in-vivo as well. To enable more widespread use, as well as development of in-vivo therapies in humans, better downstream processes for lentiviral purification will have to be developed.

In this work we present the results from initial buffer optimization and following DoEs, through which we successfully increased infectious lentiviral recovery. Interestingly, salt concentration was determined as the most important factor in loading sample for high infectious recovery of lentivirus from CIM QA column. We also present results from PATfix analytics, which we used to determine sample purity and composition.

Efficient rAAV8 Capsid Quantification in Upstream Process Development with two-dimensional Liquid Chromatography

Obtaining a high concentration and a significant proportion of full recombinant adeno-associated viruses (rAAV) capsids during production is important for the success of the entire AAV bioprocess. Analyzingcomplex upstream samples is challenging and typically involves a combination of analytical methodologies, such as PCR and ELISA. However, this approach is known for being time-consuming and frequently prone to higher standard deviations. To overcome these limitations, the PATfix AAV Switcher, an automated two-columnanalytical device, was developed.

Utilizing CIMmutlus OH for efficient purification of MSC EVs

Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) have promising therapeutic potential in diverse applications, such as tissue regeneration and immunomodulation. On the pathway to the clinic, there is a substantial need for development of scalable methods for EV production and isolation. Moreover, advancements in analytical tools for characterization of EVs are necessary to ensure a consistent product. Here, we showcase an integrative approach combining upstream, downstream and analytical processes for successful generation of MSC EVs.